BiotechTube
SRS Medical

SRS Medical

Bellevue, United States· Est.
srsmedical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.1M

Overview

SRS Medical, founded in 1990, has developed a specialized portfolio targeting the diagnosis and management of male LUTS/BPH. Its core offering combines the non-invasive UroCuff® Test for pressure-flow diagnostics, the Spanner® temporary prostatic stent to eliminate catheters, the VP™ Test for catheterized patients, and the UroReport.com software platform for clinical decision support. The company's integrated approach seeks to address critical gaps in BPH care, such as delayed interventions and lack of standardization, by using bladder function data to drive patients to the appropriate level of care. This positions SRS Medical as a solutions provider aiming to improve clinical efficiency and patient satisfaction in a large, aging demographic.

UrologyMen's Health

Technology Platform

Integrated platform combining non-invasive and catheter-compatible urodynamic diagnostic devices (UroCuff®, VP™ Test) with a cloud-based clinical decision support software (UroReport.com) to guide management of male LUTS/BPH based on bladder function data.

Funding History

2
Total raised:$2.1M
Debt$1.8M
Grant$300K

Opportunities

The large and growing aging male population with BPH creates a substantial addressable market.
The shift towards value-based care in healthcare provides a tailwind for solutions that standardize pathways, improve outcomes, and reduce costs, such as SRS Medical's integrated platform.
The Spanner® stent addresses a high-need segment (men in retention) with a compelling catheter-alternative, tapping into efforts to reduce catheter-associated complications.

Risk Factors

Slow adoption by urologists accustomed to traditional practice patterns and the challenge of changing clinical protocols pose significant commercial risks.
Reimbursement uncertainty or challenges for its diagnostic tests and the Spanner® procedure could limit market penetration.
Competition from established urodynamics companies, new minimally invasive surgical technologies, and potential software-based decision support tools from larger players presents an ongoing threat.

Competitive Landscape

SRS Medical competes in several segments: in urodynamics with traditional invasive systems from companies like Laborie and Medtronic; in BPH surgery with minimally invasive device makers (e.g., Boston Scientific's UroLift, BTG's Rezum); and in catheter alternatives with various urinary catheter manufacturers. Its unique integration of non-invasive diagnostics with decision support software differentiates it, but it must compete for mindshare and procedural volume within urology practices.

More companies in United States →